Literature DB >> 7539478

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.

S N Iyer1, J S Wild, M J Schiedt, D M Hyde, S B Margolin, S N Giri.   

Abstract

There are no clinically efficacious drugs available for preventing the development of pulmonary fibrosis (PF). In the present study, we tested the antifibrotic potential of pirfenidone (PD) in the bleomycin (BL) hamster model of PF. Hamsters were intratracheally instilled with isotonic saline solution or BL (7.5 U/kg/5 ml). The animals were fed control diet containing 0.5% PD or the same diet without the drug 2 days before and throughout the study. The four groups were as follows: saline-instilled and fed the control diet (SCD); saline-instilled and fed the same diet containing PD (SPD); BL-instilled and fed the control diet (BCD); and BL-instilled and fed the same diet containing PD (BPD). The animals were killed at 21 days after intratracheal instillation and their lungs processed for various assays. The lung hydroxyproline levels, an index of PF, in SCD, SPD, BCD, and BPD groups were 949, 970, 1759, and 990 micrograms/lung, respectively. The SOD activity and malondialdehyde equivalent levels in the corresponding groups were 443, 524, 612, and 499 units/lung and 56, 49, 108, and 63 nmol/lung, respectively. The lung prolyl hydroxylase activities in the SPD, BCD, and BPD groups were 87%, 147%, and 93% of the control (SCD) group (4.2 x 10(4) dpm/lung/30 minutes), respectively. The lung myeloperoxidase activities were 97%, 236%, and 159% of the control group (0.73 units/lung), respectively. BL alone caused significant increases in all the biochemical markers of lung toxicity, and dietary intake of PD minimized the BL toxicity as reflected by significant decreases in all the above markers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539478

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  47 in total

Review 1.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

2.  Pirfenidone.

Authors:  Luca Richeldi; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-07       Impact factor: 84.694

3.  Mitogen-activated Protein Kinase-activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis.

Authors:  Jiurong Liang; Ningshan Liu; Xue Liu; Jessica Monterrosa Mena; Ting Xie; Yan Geng; Caijuan Huan; Yanli Zhang; Forough Taghavifar; Guanling Huang; Adrianne Kurkciyan; Vivian Barron; Dianhua Jiang; Paul W Noble
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

Review 4.  Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Authors:  Noam Jacob; Stephan R Targan; David Q Shih
Journal:  United European Gastroenterol J       Date:  2016-05-10       Impact factor: 4.623

Review 5.  Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

Authors:  Sunad Rangarajan; Morgan L Locy; Tracy R Luckhardt; Victor J Thannickal
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 6.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

Review 7.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

8.  Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.

Authors:  Huijuan Xiao; Xiaoxi Huang; Shiyao Wang; Zheng Liu; Run Dong; Dingyun Song; Huaping Dai
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

Review 9.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

Review 10.  Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Authors:  Pei-Suen Tsou; Andrew J Haak; Dinesh Khanna; Richard R Neubig
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.